Oslo, Norway and East Brunswick, NJ—A new review paper published in Nutrients examines the body of evidence linking vitamin K2 to factors involved in Alzheimer’s disease (AD) pathogenesis. The paper concluded that K2 has the potential to slow the progression of AD and contribute to its prevention. Researchers from the...
Oslo, Norway and East Brunswick, NJ—NattoPharma announced that a new 1.5-year placebo-controlled, randomized, open-label intervention clinical trial using MenaQ7 Vitamin K2 as MK-7 has been registered on ClinicalTrials.gov, and is scheduled to start in September 2021. The trial, titled The Effect of Vitamin K2 Supplementation on Arterial Stiffness and Cardiovascular...
Lille, France—Gnosis by Lesaffre announced its acquisition of NattoPharma, supplier of MenaQ7 solutions. According to a press release, the acquisition allows Gnosis by Lesaffre, which supplies vitaMK7, to offer to a complete portfolio of vitamin K2 solutions, adapted to each market need and to satisfy all customers. NattoPharma will join...
Oslo, Norway and East Brunswick, NJ—NattoPharma is introducing a new logo, brand identity, and website, according to a press release. “Our science has always been a driver for brand owners to join with NattoPharma,” said NattoPharma CEO Kjetil Ramsøy in the press release. “Our MenaQ7 Vitamin K2 has been the...
Oslo, Norway, and East Brunswick, NJ—A new study is adding to the evidence that statins may enhance calcium accumulation in the arterial wall by inhibiting vitamin K-dependent proteins that help protect the arteries. While statins are used to treat atherosclerotic cardiovascular disease, the press release notes that intensive statin therapy...
Oslo, Norway—NattoPharma has renewed its relationship with the University of Maastricht, according to a press release. This relationship has resulted in partnerships in the Horizon 2020 EU ITN grants EVOLuTION and INTRICARE, and in success for NattoPharma’s products. "Our work with Maastricht has helped us not only create the Vitamin...
Oslo, Norway, and Edison, NJ—A new paper published in Biocatalysis and Agricultural Biotechnology explained the association between K2 and recovery rates in individuals with COVID-19. A press release explains that vitamin K2 menaquinone-7 (MK-7 is necessary for the activation of matrix Gla protein (MGP), a protein that inhibits the calcification...
Oslo, Norway, and Edison, NJ—A new clinical trial has found that a daily dose of vitamin K2 as MenaQ7 improved vascular health, according to a press release from NattoPharma, makers of MenaQ7. The press release explains that Matrix Gla-Protein (MGP) is involved in the prevention of arterial calcification, but the...
Oslo, Norway, and Edison, NJ—A new research paper has identified the need for a vitamin K2-specific RDI, according to a press release from NattoPharma. “In this review, we highlight the specific activity of vitamin K2 based upon proposed frameworks necessary for a bioactive substance to be recommended for an RDI.
Oslo, Norway, and Edison, NJ—The British Medical Journal recently published an observational study that examined the association between intakes of vitamins K1 and K2 and incidence of coronary heart disease (CHD). The study found a link between K2 intake and lowered risk of CHD events. The study included 2,987 Norwegian...
